DMRADamora Therapeutics, Inc.

1. Jul 20, 2026On July 16, 2026, Damora Therapeutics, Inc., a Cayman Islands exempted company (the “Company”), entered into indemnification agreements with each of its directors and executive officers (collectively, the “Indemnitees” and, the “Indemnification Agreements”), which replaced and superseded any previous indemnification …Material agreement entered · Form 8-K
2. May 4, 2026Departure of Chief Financial Officer On April 28, 2026, the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.Director or officer change · Form 8-K
3. Apr 20, 2026Dismissal of Independent Registered Public Accounting Firm On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s …Auditor change · Form 8-K
4. Mar 10, 2026On March 6, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from “Galecto, Inc.” to “Damora Therapeutics, Inc.” (the “Name Change Amendment”)Earnings release · Form 8-K
5. Feb 11, 2026On February 10, 2026, Galecto, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,473,685 …Material agreement entered · Form 8-K
6. Feb 10, 2026Departure of Chief Executive Officer and President On February 6, 2026, the Board of Directors (the “Board”) of Galecto, Inc. (the “Company”) determined that, effective as of 12:01 a.m.Director or officer change · Form 8-K
7. Jan 6, 2026On January 6, 2026, the Company announced that the board of directors (the “Board”) of the Company appointed Sherwin Sattarzadeh as the Company’s Chief Operating Officer, effective as of January 5, 2026 (the “Effective Date”)Unregistered sale of equity · Form 8-K
8. Dec 9, 2025On December 5, 2025, the Company filed with the Delaware Secretary of State a Certificate of Correction (the “Certificate of Correction”) to the Certificate of Designation of Series C Preferred Stock to correct an inadvertent error in the number of shares of Series C Non-Voting Convertible Preferred Stock, par value …Charter/bylaw amendment or fiscal-year change · Form 8-K/A
9. Nov 10, 2025Agreement and Plan of Merger On November 10, 2025, Galecto, Inc., a Delaware corporation (the “Company” or “Galecto”), acquired Damora Therapeutics, Inc., a Delaware corporation (“Damora”), in accordance with the terms of the Agreement and Plan of Merger, dated November 10, 2025 (the “Merger Agreement”), by and among …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.